Pulnovo Medical

Focus: Pulnovo Medical is a newly founded (2024) biotechnology company focused on cardio-device innovations, particularly pulmonary artery denervation technology for treating pulmonary hypertension. Based in Shanghai, the company operates in a specialized niche within cardiovascular and metabolic disease treatment.

Oncology Cardiovascular Metabolic Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Pulnovo Medical

AI assessmentNot Hiring

No open roles listed right now. Follow Pulnovo Medical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

PADN

Pulmonary Arterial Hypertension

N/A

Clinical Trials (1)

NCT03282266Safety and Efficacy of Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension

N/A

Help build intelligence for Pulnovo Medical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage entry opportunity in a novel device modality (pulmonary artery denervation) with Phase 3 program advancing toward potential regulatory approval
Focused pipeline targeting high unmet medical need in pulmonary hypertension, a rare but serious indication with limited treatment options
Shanghai headquarters positions you at the center of Asia's growing biotech ecosystem with potential for regional market expansion

Watch Out For

Extreme early-stage risk: company founded in 2024 with no disclosed funding, revenue, or employee count makes long-term stability uncertain
No active job openings currently listed and minimal public visibility on company structure, leadership, or operational capacity raises execution risk

Generated by Claude from Pulnovo Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Enhancor™ Radiofrequency Catheter, Pulnovo Medical

Pulmonary Hypertension

N/A

Clinical Trials (1)

NCT07039604Real-World Study of PADN for the Treatment of PAH

N/A

Pulmonary Artery Denervation

Pulmonary Hypertension

N/A

Clinical Trials (1)

NCT05996562Study for Evaluation of Safety and Efficacy of PADN to Treat Combined Post- and Pre- Capillary Pulmonary Hypertension Associated With Chronic Heart Failure（PADN-CpcPH-PILOT）

N/A

Pulmonary Artery Denervation

Pulmonary Hypertension

N/A

Clinical Trials (1)

NCT07214376A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

N/A

Pulmonary arterial denervation

Pulmonary Hypertension

Phase 3

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 4 clinical trials

Top TAs: Cardiovascular

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Cardiovascular

4 pipeline

Marketed

Pipeline